Onartuzumab (MetMab)did not improve PFS when combined with erlotinib (Tarceva) in the METLung trial.
Adding the novel anti-MET monoclonal antibody onartuzumab (MetMab) to EGFR mutation-targeted therapy did not impact outcomes in a pivotal trial, although other findings suggested it may have been the population rather than the target at fault.
Progression-free survival came out nearly identical for the drug added to erlotinib (Tarceva) as with erlotinib alone (median 2.7 versus 2.6 months, P=0.92), David R. Spigel, MD, of the Sarah Cannon Research Institute in Nashville, Tenn., and colleagues found in the METLung trial.
Overall survival actually trended in favor of erlotinib alone (9.1 months versus 6.8 on the combination, P=0.07), the group reported here at the American Society of Clinical Oncology meeting.
Read the report here: http://bit.ly/1kNH8uO
Source: Medpage Today
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen